POU2F3 facilitates the progression to NEPC and represents a potential biomarker to identify patients who are likely to develop resistance to AR-targeted therapies.
Determine the causality of POU2F3 as a driver of CRPC to NEPC transition.
Evaluate the sensitivity of POU2F3-expressing cells to AR-targeted therapy.
To utilize the SEER-Medicare linked database to further understand the potential role of comorbidities in racial/ethnic differences in localized prostate cancer outcomes as well as the use of active surveillance.
Assess racial/ethnic variation in comorbidity burden and survival among older patients with localized prostate cancer in SEER-Medicare.
Examine racial/ethnic variation in comorbidity burden and use of active surveillance for men with low-risk or favorable intermediate-risk localized prostate cancer in SEER-Medicare.
Explore racial/ethnic variation in comorbidity burden among prostate cancer patients in New York City in relation to neighborhood social determinants of health.
patients with high BRCA-loss signature score assessed in CTCs will achieve a better clinical response to PSMA-TRTs. Furthermore, we hypothesize that transcriptomic analysis of CTCs will reveal additional molecular pathways associated with clinical response to PSMA-TRTs.
To determine the association between BRCA-loss signature and clinical response to PSMA-TRTs.
To perform untargeted CTC transcriptomic analysis to identify additional molecular pathways associated with response/resistance to PSMA-TRTs.
In this proposal we aim to develop and credential a translational research tool that delivers image-guided prostate SBRT that is a dosimetrically accurate and clinically relevant therapeutic radiation dose.
To evaluate if advanced imaging (cone-beam CT) on the small animal radiation research platform (SARRP) facilitates target delineation of orthotopic prostate tumors and identification of organs-at-risk (bladder, rectum, bowel) to facilitate image-guided SBRT.
To measure radiation dosimetry to therapeutically irradiated orthotopic prostate tumors and adjacent normal tissues and organs (bladder, rectum, bowel) in mice undergoing image-guided prostate SBRT
To monitor therapeutic response to image-guided SBRT using volumetric/anatomic (MRI) and bioluminescence imaging (BLI) in irradiated and non-irradiated orthotopic tumors.